Sub-Total: $0.00 USD
Have questions about this assay kit?
Human MC4R Reporter Assay Kit
Product Description and Product Data
This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Melanocortin type 4 Receptor (MC4R, ACTHR). INDIGO’s MC4R reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the MC4R. In addition to MC4R Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against MC4R. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.
Features
Clear, Reproducible Results
- All-Inclusive Assay Systems
- Exceptional Cell Viability Post-Thaw
- Consistent Results Lot to Lot
Product Specifications
| Target Type | GPCR | ||
| Species | Human | ||
| Receptor Form | Hybrid | ||
| Assay Mode | Agonist, Antagonist | ||
| Kit Components |
| ||
| Shelf Life | 6 months | ||
| Shipping Requirements | Dry Ice | ||
| Storage temperature | -80C |
Data
Target Background
The melanocortin receptor system is important in the regulation of several physiological functions such as skin pigmentation, steroidogenesis, energy homeostasis, cardiovascular regulation, and inflammation. The melanocortin receptors are G-protein coupled receptors which bind in addition to adrenocorticotropic hormone (ACTH), one or more of the melanocortin stimulating hormones (α-MSH, β-MSH, or γ-MSH).
Upon ligand binding, MC4R undergoes a conformational change that triggers the activation of stimulatory G (Gs) proteins via an exchange of GDP with GTP, followed by the activation of Protein kinase A and adenylate cyclase, and the production of the second messenger cAMP. These receptors have been targeted for drug development for the treatment of various skin disorders, skin cancer, obesity, inflammatory diseases and neurological disorders1. Consequently, the melanocortin receptors continue to command much interest as targets for drug development and drug safety screening.
Product Documentation
Citations
Also available as a service